Каприн А.Д., Старинский В. В., Петрова Г. В. (ред.). Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России, 2016. 250 с.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, Mar 1, 136(5): E359-86.

de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol., 1997, 15(2): 808-815.

Kohne C-H, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg U, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichinitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol., 2003, 21(20): 3721-3728.

Thirion P, Michielis S, Pignon JP, Buyse M, Braud AC, Carlson RW, O´Connell M, Sargent P, Piedbois P, Meta-analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an update metaanalysis. J. Clin. Oncol., 2004, 22(18): 3766-3775.

Giantonio B, Catalano P, Meropol N, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol., 2007, 20: 1539-1544.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann. Oncol., 2014, 25(1): 107-16.

Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA, Bonnetain F, Watanabe T, Boukovinas I, Renfro LA, Grothey A, Niedzwiecki D, Torri V, Andre T, Sargent DJ, Iveson T. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J. Clin. Oncol., 2017, 35(suppl, abstr LBA1).

Nordlinger B, Sorbye H, Glimelius B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC40983): longterm results of a randomised, controlled, phase 3 trial. Lancet Oncol, 2013, 14(12): 1208-1215.

Sorbye H, Mauer M, Gruenberger T et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann. Surg., 2012, 255(3): 534-539.

Adam R, Bhangui P, Poston G et al. Is perioperative chemotherapyuseful for solitary, metachronous, colorectal liver metastases? Ann. Surg., 2010, 252(5): 774-787.

Zhu D, Zhong Y, Wei Y et al. Effect of neoadjuvantchemotherapy in patients with resectable colorectal liver metastases. PLoS One, 2014, 9(1): e86543.

John Primrose et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. The Lancet Oncology, 2014 May, 15(6): 601-611.

Falcone A, Ricci S, Brunetti C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaloplatin, and irinotecan (FOLFOXIRI) compared to infusionalfluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. J. Clin. Oncol., 2015, 25: 1670-76.

Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated onerallsurvivaland molecular subgroup analy sis of the open-label, phase 3 TRIBE study. Lancet Oncol, 2015, 16: 1306-15.

Schmoll H-J, Garlipp B, Junghanss C et al. CHARTA: FOLFOX+bevacizumab +/irinotecan in advanced colorectal cancer (CRC). Final results of the randomized phase II trial of the AIO (KRK 0209).

Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict longterm survival. Ann. Surg., 2004, 240(4): 644-657.

Adam R, Wicherts DA, Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J. Clin. Oncol., 2009, 27(11): 1829-1835.

Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol., 2005, 16(8): 1311-1319.

Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol., 2004, 22: 229-237.

Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/ leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J. Clin. Oncol., 2008, 26(36): 5910-5917.

Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol., 2007, 25(30): 4779-4786.

Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg., 2004, 240(4): 644-657.

Baize N, Gerard B, Bleiberg H et al.Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol. Clin. Biol., 2006, 30: 1349-1353.

Gruenberger T, Bridgewater JA, Chau I et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA. Jour. Of Clin. Oncol., 2013, 31(15, suppl.): 3619.

Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg., 2009, 249: 420-425.

Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemoth. Pharmacol., 2008, 62(2): 195-201.

Vasile E, Masi G, Fornaro L et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer., 2009, 100(11): 1720-1724.

Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol., 2007, 25(13): 1670-1676.

Kemeny N, Capanu M, D’Angelica M et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Annals of Oncology, 2009, 20: 1236–1241.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, BergslandE.Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 1, 21(1): 60-5.

Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 2005 Jun 1, 23(16): 3697-705.

Saunders MP, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D, Jonker DJ, Stuart Osborne, Markus Loeffler, Daniel Waterkamp, David Cunningham. Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer. J. Clin. Oncol., 2013 May.

Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004, 22: 1209–14.

Koopman M, Seymour Mt, Punt Cj. The CAIRO and FOCUS studies: which lesson is to be learned? Oncologist, 2009, 14: 192-193, author reply 194-196.

Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 2007, 370: 135-142.

Seymour MT, Maughan TS, Ledermann Ja et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet, 2007, 370: 143-152.

Modest Dominik, Fischer von Weikersthal Ludwig, Decker Thomas, Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011) – study. Annals of Oncology, 2017, 28(Supple 3): 147-148

А De Cramont et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J Clin Oncol, 2009, 27(15 Suppl.): 4024.

Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapybe discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol, 2009, 27: 572733.

Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomizedstudy of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-gofashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol, 2006, 24: 394-400.

Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuousoxaliplatin and fluoropyrimidine combination chemotherapyfor first-line treatment of advanced colorectal cancer: resultsof the randomised phase 3 MRC COIN trial. Lancet Oncol, 2011, 12: 642-53.

Labianca R, Sobrero A, Isa L, et al. Intermittent versus continuouschemotherapy in advanced colorectal cancer: a randomized ‘GISCAD’ trial. Ann Oncol, 2011, 22: 1236-42.

Luo HY, Li YH, Wang W et al. Single-Agent Capecitabineas Maintenance Therapy AfterInduction of XELOX (or FOLFOX) in FirstLineTreatment of Metastatic Colorectal Cancer: Randomizedclinical trial of efficacy and safety. Chin J Cancer, 2016, 35: 13.

Simkens LH, van Tinteren H, May A et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet, 2015, 385: 1843-1852.

André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med, 2004 Jun 3, 350(23): 2343-51.

Mols F, Beijers T, Lemmens V et al. Chemotherapy-Induced Neuropathy and Its AssociationWith Quality of Life Among 2to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry. J Clin Oncol, 2013 Jul 20, 31(21): 2699-707.

Durand JP, Deplanque G, Montheil V et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology, 2012, 23: 200–205.

Zimmerman C, Atherton PJ, Pachman D et al. MC11C4: a pilot randomized, placebo-controlled, double-blindstudy of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer, 2016 Mar, 24(3): 1071-8.

Salehi Z, Roayaei M. Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial. Int J Prev Med, 2015 Nov 2, 6: 104.

de Andrade D, Teixeira M J, Galhardoni R et al. Pregabalin for the Prevention of OxaliplatinInduced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist, 2017 Jun 26. pii: theoncologist. 2017-0235.

Esfahani A, Somi M, Ayromlou H et al. The effect of n-3 polyunsaturated fattyacids on incidence and severity ofoxaliplatin induced peripheral neuropathy: a randomized controlled trial. Biomark Res, 2016 Jun 23, 4: 13.

Jordan B, Jahn F, Beckmann J et al. Calcium and Magnesium Infusions for thePrevention of Oxaliplatin-Induced Peripheral Neurotoxicity. A Systematic Review Oncology, 2016, 90(6): 299-306.

Hochster H, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of the CONcePT trial. Ann Oncol, 2014, 25: 1172–1178.

Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusionand no impact on its efficacy. J Clin Oncol, 2008, 26: 1188–1189, author reply 1189–1190.